S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Consumers are increasingly pushing back against price increases — and winning
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
AI Stock Caught Trading Under Secret Name (Ad)
Federal prosecutors accuse a New Mexico woman of fraud in oil and gas royalty case
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Consumers are increasingly pushing back against price increases — and winning
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
AI Stock Caught Trading Under Secret Name (Ad)
Federal prosecutors accuse a New Mexico woman of fraud in oil and gas royalty case
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Consumers are increasingly pushing back against price increases — and winning
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
AI Stock Caught Trading Under Secret Name (Ad)
Federal prosecutors accuse a New Mexico woman of fraud in oil and gas royalty case
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Consumers are increasingly pushing back against price increases — and winning
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
AI Stock Caught Trading Under Secret Name (Ad)
Federal prosecutors accuse a New Mexico woman of fraud in oil and gas royalty case
NYSE:CANF

Can-Fite BioPharma (CANF) Stock Price, News & Analysis

$2.06
-0.04 (-1.90%)
(As of 02/23/2024 ET)
Today's Range
$2.06
$2.18
50-Day Range
$1.93
$2.20
52-Week Range
$1.52
$3.33
Volume
68,749 shs
Average Volume
21,220 shs
Market Capitalization
$7.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Can-Fite BioPharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
628.2% Upside
$15.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Can-Fite BioPharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.85) to ($0.27) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.69 out of 5 stars


CANF stock logo

About Can-Fite BioPharma Stock (NYSE:CANF)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

CANF Stock Price History

CANF Stock News Headlines

Historical Prices
Can-Fite BioPharma Ltd. (CANF)
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
StockNews.com Begins Coverage on Can-Fite BioPharma (NYSE:CANF)
Can Fite Biopharma Ltd (CANF)
Can Fite Biopharma Ltd ADR (CANF)
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
See More Headlines
Receive CANF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/30/2023
Today
2/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
8
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$18.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+628.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-10,170,000.00
Net Margins
-1,146.62%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$810,000.00
Book Value
$1.33 per share

Miscellaneous

Free Float
3,512,000
Market Cap
$7.29 million
Optionable
Not Optionable
Beta
1.52
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Pnina Fishman Ph.D. (Age 76)
    Founder, Chief Scientific Officer & Executive Chairman
    Comp: $644k
  • Mr. Motti Farbstein (Age 60)
    CEO & Chief Operating and Financial Officer
    Comp: $414k
  • Dr. Sari Fishman Ph.D. (Age 52)
    Vice President of Business Development
    Comp: $325k
  • Dr. Ilan Cohn Ph.D. (Age 70)
    Co-Founder & Director
  • Dr. Stephen A. Harrison FACP
    M.D., Member of Clinical Advisory Board & Consulting Chief Medical Officer














CANF Stock Analysis - Frequently Asked Questions

Should I buy or sell Can-Fite BioPharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Can-Fite BioPharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CANF shares.
View CANF analyst ratings
or view top-rated stocks.

What is Can-Fite BioPharma's stock price target for 2024?

1 Wall Street analysts have issued 1 year price targets for Can-Fite BioPharma's shares. Their CANF share price targets range from $12.00 to $18.00. On average, they expect the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 628.2% from the stock's current price.
View analysts price targets for CANF
or view top-rated stocks among Wall Street analysts.

How have CANF shares performed in 2024?

Can-Fite BioPharma's stock was trading at $2.20 on January 1st, 2024. Since then, CANF stock has decreased by 6.4% and is now trading at $2.06.
View the best growth stocks for 2024 here
.

How were Can-Fite BioPharma's earnings last quarter?

Can-Fite BioPharma Ltd. (NYSE:CANF) issued its quarterly earnings data on Thursday, November, 30th. The company reported ($0.43) EPS for the quarter, meeting analysts' consensus estimates of ($0.43). The firm had revenue of $0.20 million for the quarter, compared to analysts' expectations of $0.20 million. Can-Fite BioPharma had a negative trailing twelve-month return on equity of 143.59% and a negative net margin of 1,146.62%.

When did Can-Fite BioPharma's stock split?

Shares of Can-Fite BioPharma reverse split on Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Can-Fite BioPharma's major shareholders?

Can-Fite BioPharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Armistice Capital LLC (4.36%) and Schechter Investment Advisors LLC (0.57%).

How do I buy shares of Can-Fite BioPharma?

Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:CANF) was last updated on 2/25/2024 by MarketBeat.com Staff